Clinical TrialMay 4, 2026, 09:02 AM
Alpha Tau Alpha DaRT Pancreatic Cancer Trials Show 100% Local Control
AI Summary
Alpha Tau Medical Ltd. announced updated pooled results from two first-in-human clinical trials of its Alpha DaRT® therapy for pancreatic ductal adenocarcinoma (PDAC). The trials demonstrated a 100% local disease control rate in evaluable patients and a favorable safety profile, with only 8 device-associated adverse events in 7 of 26 subjects, nearly all resolving within two weeks. These results, presented at DDW 2026, support the potential of Alpha DaRT as an intratumoral treatment for challenging pancreatic cancer cases, including heavily pre-treated patients.
Key Highlights
- Achieved 100% local disease control rate in 19 evaluable patients with pancreatic adenocarcinoma.
- Observed 15 (79%) patients with stable disease and 4 (21%) with partial response.
- Reported 8 device-associated adverse events in 7 of 26 subjects (27%).
- Nearly all device-associated adverse events resolved within two weeks.
- Trials included patients ineligible for chemotherapy and those with up to four prior lines.
- Treatment delivered via streamlined outpatient endoscopic ultrasound (EUS)-guided procedure.
- Results presented at Digestive Disease Week (DDW) 2026.